Insomnia News and Research

Latest Insomnia News and Research

Change in attitude may ease chronic pain by aiding sleep: Study

Chronic pain sufferers who learn to dwell less on their ailments may sleep better and experience less day-to-day pain, according to results of research conducted on 214 people with chronic face and jaw pain.

26 Apr 2012

FDA issues complete response letter to Takeda’s NDAs for type 2 diabetes investigational therapies

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. today announced that the company received a complete response letter from the United States (U.S.) Food and Drug Administration (FDA) regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone.

26 Apr 2012

Researchers develop Bergen Work Addiction Scale

Researchers from Norway and the United Kingdom have developed a new instrument to measure work addiction: The Bergen Work Addiction Scale. The new instrument is based on core elements of addiction that are recognised as diagnostic criteria for several addictions.

24 Apr 2012

Poor sleep not a significant predictor of fibromyalgia pain intensity

Patients coping with the complex pain disorder fibromyalgia often have difficulty sleeping, and a new study published in The Journal of Pain reports that despite the negative quality of life implications, poor sleep is not a significant predictor of fibromyalgia pain intensity and duration.

23 Apr 2012

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

MSD, known as Merck in the United States and Canada, announced final results from a Phase III, open-label study designed to compare the impact of two anaemia management strategies on sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) genotype 1 infection treated with VICTRELIS(boceprevir) in combination with PEGINTRON and ribavirin.

20 Apr 2012

Link between insomnia and severity of perceived tinnitus symptoms

For the more than 36 million people plagued by tinnitus, insomnia can have a negative effect on the condition, worsening the functional and emotional toll of chronic ringing, buzzing, hissing or clicking in the head and ears, according to a new study from Henry Ford Hospital in Detroit.

19 Apr 2012

Biogen Idec launches FAMPYRA in Canada

Today, Biogen Idec Canada announces that FAMPYRA (fampridine sustained release tablets or fampridine SR) is now available for prescription for patients living with multiple sclerosis (MS) in Canada.

12 Apr 2012

Takeda enters definitive agreement to acquire URL Pharma

Takeda Pharmaceutical Company Limited and URL Pharma Inc. jointly announced that Takeda's wholly-owned subsidiary, Takeda America Holdings, Inc. and URL Pharma have entered into a definitive agreement to acquire URL Pharma – a privately-held pharmaceutical company headquartered in Philadelphia, Pennsylvania, for an upfront payment of $800 million and future performance-based contingent earn out payments.

12 Apr 2012

Siemens announces integrated imaging solution for detection of amyloid plaques

Siemens Healthcare is the first company worldwide to announce a complete integrated diagnostic imaging solution proposed for the detection of amyloid plaques — one of the necessary pathological features of Alzheimer's disease— in the living brain.

From Siemens Healthineers 11 Apr 2012

Lilly, Avid receive FDA approval for Amyvid to treat Alzheimer's

Eli Lilly and Company and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.

7 Apr 2012

Purdue Pharma launches Intermezzo for middle-of-the-night insomnia

Purdue Pharma L.P. announced today that Intermezzo (zolpidem tartrate) sublingual tablet CIV is now available in 1.75 mg and 3.5 mg dosage strengths by prescription in retail pharmacies nationwide.

6 Apr 2012

Post-operative complications after oesophageal cancer surgery may cause other health problems

Oesophageal cancer is a very serious form of cancer that, if not fatal, requires extensive surgery. A new study from Karolinska Institutet in Sweden shows that when serious complications arise after surgery for oesophageal cancer, many patients suffer other health problems, such as breathlessness, fatigue, insomnia and eating problems, for five years afterwards.

4 Apr 2012

UCB receives FDA approval for Neupro to treat idiopathic Parkinson's, RLS

UCB announced today that the U.S. Food and Drug Administration (FDA) approved Neupro (Rotigotine Transdermal System) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson's disease (PD) and as a treatment for moderate-to-severe primary Restless Legs Syndrome.

3 Apr 2012

Regular walking regimen can benefit cancer survivors

Researchers have affirmed that pancreatic cancer patients can literally take a step-by-step approach to combat fatigue. A study published in the April issue of the Journal of the American College of Surgeons reports that patients who underwent an operation as part of their cancer treatment and then started a regular walking regimen experienced less fatigue than cancer survivors who did not do the walking program.

2 Apr 2012

Sleep enhances emotionally positive memories

Sleep plays a powerful role in preserving our memories. But while recent research shows that wakefulness may cloud memories of negative or traumatic events, a new study has found that wakefulness also degrades positive memories. Sleep, it seems, protects positive memories just as it does negative ones, and that has important implications for the treatment of post-traumatic stress disorder.

2 Apr 2012

Depression more prevalent among stroke and transient ischemic attack survivors

Depression is more prevalent among stroke and transient ischemic attack survivors than in the general population, researchers reported in the American Heart Association's journal Stroke.

29 Mar 2012

Roaring snores could be sounds of obstructive sleep apnea

Roaring snores that rumble a room or violent snorts for breath during sleep could be sounds of obstructive sleep apnea. While a true diagnosis is only possible with a sleep study, if left untreated, the sleep disorder could be fatal.

28 Mar 2012

Teva, IVAX receive FDA approval for generic Lexapro to treat depression and GAD

The U.S. Food and Drug Administration today approved the first generic Lexapro (escitalopram tablets) to treat both depression and generalized anxiety disorder in adults.

27 Mar 2012

Rifaximin and lubiprostone offer best options for patients with IBS

Cedars-Sinai researchers have determined that two prevalent drug therapies - rifaximin and lubiprostone - offer some of the best options for treating irritable bowel syndrome, a widespread disorder that affects up to one in five Americans.

26 Mar 2012

Heptares exercises exclusive option to license new A2A antagonist for CNS disorders

Heptares Therapeutics, the leading GPCR drug discovery company, announces that an operating company of Shire PLC, the global specialty biopharmaceutical company, has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares that is currently in preclinical development.

20 Mar 2012